论文部分内容阅读
目的:评价树突状细胞(dendritic cell,DC)联合细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)治疗晚期胰腺癌患者的临床疗效。方法:收集34例采用DC-CIK细胞治疗的晚期胰腺癌患者,采取自身对照原则,分为自身对照组和治疗组,根据治疗组所经历的治疗疗程,治疗组分为治疗组2、治疗组3、治疗组4,分别代表经过2个疗程,3个疗程,4个疗程治疗的治疗组患者。比较自身对照组和治疗组两组患者的近期生存质量差异,并比较不同治疗组患者的近期生存质量差异。结果:治疗组患者的单项近期生存质量指标(食欲、睡眠、精神、体力)明显改善,同自身对照组比较有统计学意义;不同治疗组患者的近期生存质量有明显差异,疗程越长总体近期生存质量越高。结论:DC-CIK细胞生物免疫治疗对晚期胰腺癌可在一定程度上提高近期临床疗效,减缓晚期胰腺癌的疾病进展,值得临床推广应用。
Objective: To evaluate the clinical efficacy of dendritic cell (DC) combined with cytokine-induced killer (CIK) in the treatment of patients with advanced pancreatic cancer. Methods: Thirty-four patients with advanced pancreatic cancer treated with DC-CIK cells were collected and divided into self-control group and treatment group according to the self-control principle. According to the treatment course experienced by the treatment group, the treatment group consisted of treatment group 2, treatment group 3, treatment group 4, representing the treatment group after 2 courses, 3 courses and 4 courses respectively. The differences in recent quality of life between the two groups in the control and treatment groups were compared and the recent differences in quality of life between the different treatment groups were compared. Results: The individual recent quality of life indicators (appetite, sleep, mental, physical) of patients in the treatment group were significantly improved compared with the control group; the recent quality of life of the patients in different treatment groups was significantly different; The higher the quality of life. Conclusion: DC-CIK cell immunotherapy for advanced pancreatic cancer can improve the short-term clinical curative effect to a certain extent and slow the disease progression of advanced pancreatic cancer, which deserves clinical application.